Search Results - "Laffin, Luke J"

Supplements for Lipid Lowering: What Does the Evidence Show? by Mirzai, Saeid, Laffin, Luke J.

“…Purpose In this review, the regulation, proposed hypolipidemic mechanism, and efficacy of common dietary supplements (DSs) marketed for cardiovascular health…”
Get full text

Hypertension: A Companion to Braunwald's Heart Disease by Bakris, George L, Sorrentino, Matthew, Laffin, Luke J

Get full text

Has the Sun Set on Nighttime Dosing in Uncomplicated Hypertension? by Laffin, Luke J, Bakris, George L

Get full text

Overcoming toxicity and side-effects of lipid-lowering therapies by Wilkinson, Michael J., MD, Laffin, Luke J., MD, Davidson, Michael H., MD

“…Lowering serum lipid levels is part of the foundation of treating and preventing clinically significant cardiovascular disease. Recently, the American Heart…”
Get full text

Newer alternatives for resistant hypertension: Beyond 2022 paradigms by Laffin, Luke J., Briasoulis, Alexandros, Bakris, George L.

“…Given the increased incidence of resistant hypertension and no novel agents to manage hypertension for more than 15 years, there has been an increase in the…”
Get full text

National, regional, and urban-rural patterns in fixed-terrestrial broadband internet access and cardiac rehabilitation utilization in the United States by Van Iterson, Erik H., Laffin, Luke J., Cho, Leslie

“…Sparse patterns in fixed-terrestrial broadband internet access are predominantly observed among older adults and low income areas, which are interrelated…”
Get full text

Geographical and Urban-Rural Disparities in Cardiac Rehabilitation Eligibility and Center-Based Use in the US by Van Iterson, Erik H, Laffin, Luke J, Bruemmer, Dennis, Cho, Leslie

Get more information

Association of pulse pressure with death, myocardial infarction, and stroke among cardiovascular outcome trial participants by Agarwal, Neel, St. John, Julie, Van Iterson, Erik H., Laffin, Luke J.

“…Prior evidence demonstrates that pulse pressure (PP), a surrogate marker of arterial stiffness, is an independent risk factor for mortality and major adverse…”
Get full text

Expanding the availability of cardiac rehabilitation by offering a virtual option: Forecasting the financial implications by Van Iterson, Erik H., Laffin, Luke J., Cho, Leslie

Get full text

All‐cause mortality predicted by peak oxygen uptake differs depending on spirometry pattern in patients with heart failure and reduced ejection fraction by Van Iterson, Erik H., Cho, Leslie, Tonelli, Adriano, Finet, J. Emanuel, Laffin, Luke J.

“…Aims In patients with heart failure and reduced ejection fraction (HFrEF), it remains unclear how exacerbated impairments in peak exercise oxygen uptake…”
Get full text

Endothelin Antagonism and Hypertension: An Evolving Target by Laffin, Luke J., MD, Bakris, George L., MD

“…Summary The impact of endothelin antagonism for the management of hypertension is a topic explored in multiple preclinical and clinical studies…”
Get full text

Rise in Blood Pressure Observed Among US Adults During the COVID-19 Pandemic by Laffin, Luke J., Kaufman, Harvey W., Chen, Zhen, Niles, Justin K., Arellano, Andre R., Bare, Lance A., Hazen, Stanley L.

Get full text

Exercise prescription for the prevention and treatment of arterial hypertension: targeting blood pressure is not necessarily the goal by Van Iterson, Erik H, Laffin, Luke J

Get more information

Reply: The Nuance of Studying and Prescribing Supplements by Laffin, Luke J., Nissen, Steven E.

Get full text

Are dietary supplements beneficial in lowering cholesterol? SPORT reflections and the path forward by Laffin, Luke J, Bruemmer, Dennis, Nissen, Steven E

Get full text

Artificial Intelligence and Hypertension: Recent Advances and Future Outlook by Chaikijurajai, Thanat, Laffin, Luke J, Tang, Wai Hong Wilson

“…Abstract Prevention and treatment of hypertension (HTN) are a challenging public health problem. Recent evidence suggests that artificial intelligence (AI) has…”
Get full text

Lp(a) - an overlooked risk factor by Laffin, Luke J., Nissen, Steven E.

“…Lipoprotein(a) (Lp(a)) is an increasingly discussed and studied risk factor for atherosclerotic cardiovascular disease and aortic valve stenosis. Many genetic…”
Get full text

Obicetrapib—the Rebirth of CETP Inhibitors? by Chang, Bliss, Laffin, Luke J., Sarraju, Ashish, Nissen, Steven E.

“…Purpose of Review To provide perspective on the current development status, and potential future role, of obicetrapib, a third-generation cholesterylester…”
Get full text

Assessing Wide Pulse Pressure Hypertension: Data Beyond the Guidelines by Bakris, George L., Laffin, Luke J.

“…[Display omitted]…”
Get full text

Intersection Between Chronic Kidney Disease and Cardiovascular Disease by Laffin, Luke J., Bakris, George L.

“…Purpose of Review The incidence of chronic kidney disease is increasing worldwide, and the previously decreasing incidence of cardiovascular disease has now…”
Get full text